Open Label Study Evaluating DUOBRII in Psoriasis Patients Being Treated With Biologic Agents.
Who is this study for? Adults with psoriasis with 2%-10% BSA
What treatments are being studied? Duobrii
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY
12 weeks DUOBRII to patients with 2%-10% BSA who are receiving biologic therapy for at least 24 weeks
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Male or female adult ≥ 18 years of age;
• Diagnosis of chronic plaque-type
• Psoriasis affecting 2%-10% BSA
• Patient is being treated with biologic therapy for a minimum of 24 weeks
• Able and willing to give written informed consent prior to performance of any study-related procedures
Locations
United States
New Jersey
Psoriasis Treatment Center of Central New Jersey
RECRUITING
East Windsor
Contact Information
Primary
Jerry Bagel, MD
dreamacres1@aol.com
6094434500
Backup
Elise Nelson
enelson@windsordermatology.com
6094434500
Time Frame
Start Date: 2019-10-14
Estimated Completion Date: 2020-09-01
Participants
Target number of participants: 25
Treatments
Experimental: Open Label Duobrii
Duobrii QD
Related Therapeutic Areas
Sponsors
Leads: Psoriasis Treatment Center of Central New Jersey
Collaborators: Ortho Dermatologics